News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genmab A/S (GEN.CO) Files IND for HuMax-TF-ADC



7/18/2013 9:45:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark; July 18, 2013 – Genmab A/S (OMX: GEN) announced today the filing of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start a Phase I dose escalation trial of HuMax-TF-ADC to treat multiple solid tumors. A maximum of 78 patients with cancer of the ovary, cervix, endometrium, bladder, prostate, head & neck, esophagus or lung that have failed or are not eligible for standard treatments will be enrolled in the study. The safety and tolerability of HuMax-TF-ADC will be established during a dose escalation part of the study. This will be followed by a cohort expansion part that will investigate longer-term safety and potential signs of anti-tumor activity.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES